Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2020 Dec 17;41(2):822–836. doi: 10.1161/ATVBAHA.120.315053

Figure 3. Recruitment of tracer-bound leukocytes, non-specific binding of the tracer, or change in plaque glycosaminoglycan content do not account for the reduction of PET signal in regressing plaques.

Figure 3.

(A) Representative 64Cu-DOTA-vMIP-II PET images and (B) quantification (n=3–4 per group) at aortic arches of Apoe−/− mice on HFD with or without leukocyte depletion. *p<0.05 by 1-way ANOVA with the Turkey post hoc test. (C) Sulfated glycosaminoglycan (sGAG) content in whole thoracic aortas from Apoe−/− mice with or without 2 weeks of AAV-mApoE treatment (n=4–5 per group). (D) Biodistribution of 64Cu-DOTA-PEG in aortas from Apoe−/− mice with or without 2 weeks of AAV-mApoE treatment, or WT mice (n=4–5 per group). All data are shown as means ± SEM.